Fusion Antibodies are happy to announce we have entered into a partnership with Swiss contract manufacturing organisation Celonic AG to collaborate on the development of high yield stable cell lines.
The deal will allow clients of Fusion Antibodies a direct & efficient supply path to clinical trial material by taking advantage of the scale-up and development capabilities of Celonic. Fusion Antibodies and Switzerland based CDMO Celonic, a leading provider of services for the development and cGMP production of biopharmaceuticals, have today announced a partnership to offer Celonic’s CHOvolution cell line development technology to our clients.
The collaboration will allow Fusion Antibodies’ clients access to the Celonic stable and high titre (>7g/l) platform at an earlier stage and at a competitive cost as the materials are non-GMP and suitable for pre-clinical development. Once a client has completed the applicable preclinical studies, the cell line can be easily transferred from Fusion to Celonic for further development & supply of clinical ready GMP material.
Our Paul Kerr, Managing Director at Fusion Antibodies commented:“We are delighted to deepen our relationship with Celonic. This partnership allows us to offer our clients a ‘one stop shop’ supply of antibody drug candidate materials from discovery right through to clinical development. Clients do not need to change to a production cell line after their R&D thereby saving time, money and adding project safety as preclinical and clinical results will be easier to compare”
Konstantin Matentzoglu added: “I am excited about this truly enabling partnership, which goes beyond a loose out-licensing/co-marketing deal. Celonic and Fusion Antibodies engage together and will offer highly aligned services to provide a safe and efficient development approach to clients worldwide.”
To find out more about Fusion Antibodies, visit our ‘About Us’ page at http://fusionantibodies.com/who-we-are/about-fusion-antibodies.
Celonic AG is privately owned CDMO based in Basel, Switzerland providing comprehensive GMP development and manufacturing services for New Biological Entities (NBEs) and Biosimilars worldwide. Applying empathy, efficiency and excellence, Celonic goes one step beyond expectations in all business aspects in order to help its clients attain their goals better, more efficiently and reliably.
Celonic’s services include the development of cell lines, production processes as well as the GMP and non-GMP manufacturing of biopharmaceutical drug substances. In addition, Celonic licenses its proprietary CHOvolution cell line technology to clients, drug developer and service provider.
Visit their website http://www.celonic.com/ to learn more.